Skip to main content
DAEWOONG PHARMA logo

DAEWOONG PHARMA — Investor Relations & Filings

Ticker · 069620 ISIN · KR7069620003 KO Manufacturing
Open in API
Filings indexed 380 across all filing types
Latest filing 2026-03-09 Audit Report / Informat…
Country KR South Korea
Listing KO 069620

About DAEWOONG PHARMA

http://crm.daewoong.co.kr/eng/main

Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, financial highlights (consolidated and separate), and details regarding the external auditor. While it contains financial data, it is a standard regulatory announcement of the audit report's submission rather than the full annual report (10-K) or a standalone audit report document (AR). Given the structure and the nature of the filing as a mandatory disclosure of audit results, it fits the 'RPA' (Report Publication Announcement) category as it announces the completion and submission of the audit report. FY 2025
2026-03-09 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure filed by Daewoong Pharmaceutical regarding the approval of a Phase 3 clinical trial for their drug 'Envlo'. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KRX). Since this is a specific regulatory announcement regarding clinical trial progress and does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2026-03-05 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Daewoong Pharmaceutical. It contains the meeting agenda, details on voting procedures, director information, and financial statements (balance sheet, income statement) to be presented at the meeting. This document is a standard proxy statement/notice of meeting sent to shareholders to inform them of the upcoming AGM and request their participation/votes. In the provided taxonomy, this fits best under 'Proxy Solicitation & Information Statement' (PSI).
2026-02-26 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights) for Daewoong Pharmaceutical. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, and proxy solicitation details. While it includes financial statements, these are provided as part of the 'Management Reference' section required for the proxy solicitation process, not as a standalone Annual Report or 10-K. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-02-26 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집결의) issued by Daewoong Pharmaceutical. It details the agenda for an upcoming Annual General Meeting, including proposals for board appointments, amendments to the articles of incorporation, and dividend-related governance. This type of document is a standard proxy solicitation material sent to shareholders to inform them of meeting details and request their votes, which falls under the Proxy Solicitation & Information Statement category.
2026-02-25 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Daewoong Pharmaceutical regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2026-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.